Biaoru Li*, Huasheng Xiao, Yong Gao, Shen Li, Xiaona Zhang, Junsong Han
Background
Primary cardiac sarcoma is rare tumor with a poor prognosis. Currently, complete surgical removal is only mode of therapy proven to show some benefits. If the tumor has metastases, it will demonstrate very unfavorable outcome. Here we reported a personalized chemotherapy to treat a patient
suffering from cardiac sarcoma with multiple metastases.
Method and findings
We obtained a pair of cardiac sarcoma CD34+ cells and normal cells from laser capture microscopy of FFPE samples and then processed the specimens RNA to perform triple microarray (Human Genome U133-plus2) to achieve genomic expression profile regarding cardiac sarcoma CD34+ cell and normal cardiac cells. After uncovering gene expression profile, gene expression signature was mined by quantitative network and targeting drugs was identified by Drug-Bank. The targeting genes were further confirmed by Q-rtPCR and selected drugs were also validated for the cardiac sarcoma by computational modeling. Finally, some of the drugs approved by FDA were selected for the patient treatment. Our method not only analyzes high genomic expression profiles in the case but it finds the specific targeting genes with their drugs through quantitative network which can control the progress of the metastatic disease.
Conclusion
We successfully select FDA approved drugs to treat the patient and achieve a partial response for the patient who has suffered from cardiac sarcoma with multiple metastases.
